State Street’s Decoy Therapeutics DCOY Stock Holding History

State Street’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4	Closed	-$28K	–	4890
2022 Q3	$28K	Hold	4	–	–	﹤0.01%	4780
2022 Q2	$30K	Hold	4	–	–	﹤0.01%	4818
2022 Q1	$57K	Hold	4	–	–	﹤0.01%	4775
2021 Q4	$71K	Hold	4	–	–	﹤0.01%	4641
2021 Q3	$145K	Hold	4	–	–	﹤0.01%	4461
2021 Q2	$151K	Buy	+4	New	+$178K	﹤0.01%	4279
2017 Q2	–	Hold	0	–	-$612K	–	3726
2017 Q1	–	Hold	0	–	–	–	3354
2016 Q4	–	Hold	0	–	–	–	3339
2016 Q3	–	Hold	0	–	–	–	3055
2016 Q2	–	Hold	0	–	–	–	3205
2016 Q1	–	Hold	0	–	–	–	3329
2015 Q4	–	Hold	0	–	–	–	3335
2015 Q3	–	Hold	0	–	–	–	3352
2015 Q2	–	Hold	0	–	–	–	3322
2015 Q1	–	Hold	0	–	–	–	3460

Other funds holding DCOY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street's DCOY Position: Q4 2022 in Review

State Street sold out of Decoy Therapeutics (DCOY) in Q4 2022, closing a stake of 4 shares — an estimated $28K sold.

State Street first reported a position in DCOY in Q2 2021 and held it in 6 quarters. The position peaked at $151K in Q2 2021. 4 funds tracked by Wall St. Rank hold DCOY as of Q4 2022.

State Street reported no remaining Decoy Therapeutics position as of Q4 2022 after selling out during the quarter.
State Street sold 4 Decoy Therapeutics shares in Q4 2022, an estimated $28K.
State Street first reported a position in Decoy Therapeutics in Q2 2021 and held it in 6 quarters.
State Street's Decoy Therapeutics position peaked at $151K in Q2 2021.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q4 2022.

Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.